These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Proton magnetic resonance spectroscopy in obsessive-compulsive disorder: a pilot investigation comparing treatment responders and non-responders. Mohamed MA, Smith MA, Schlund MW, Nestadt G, Barker PB, Hoehn-Saric R. Psychiatry Res; 2007 Nov 15; 156(2):175-9. PubMed ID: 17904826 [Abstract] [Full Text] [Related]
4. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder. Jang JH, Kwon JS, Jang DP, Moon WJ, Lee JM, Ha TH, Chung EC, Kim IY, Kim SI. Am J Psychiatry; 2006 Jul 15; 163(7):1202-7. PubMed ID: 16816225 [Abstract] [Full Text] [Related]
5. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. J Clin Psychiatry; 2009 Jun 15; 70(6):863-8. PubMed ID: 19422759 [Abstract] [Full Text] [Related]
7. The comparison of pre- and post-treatment (99m)Tc HMPAO brain SPECT images in patients with obsessive-compulsive disorder. Karadağ F, Kalkan Oğuzhanoğlu N, Yüksel D, Kıraç S, Cura C, Ozdel O, Ateşci F. Psychiatry Res; 2013 Aug 30; 213(2):169-77. PubMed ID: 23149026 [Abstract] [Full Text] [Related]
9. Proton magnetic resonance spectroscopy in pediatric obsessive-compulsive disorder: longitudinal study before and after treatment. Lázaro L, Bargalló N, Andrés S, Falcón C, Morer A, Junqué C, Castro-Fornieles J. Psychiatry Res; 2012 Jan 30; 201(1):17-24. PubMed ID: 22281202 [Abstract] [Full Text] [Related]
10. Proton magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for reduced neuronal integrity in the anterior cingulate. Tükel R, Aydın K, Ertekin E, Özyıldırım SŞ, Taravari V. Psychiatry Res; 2014 Dec 30; 224(3):275-80. PubMed ID: 25241042 [Abstract] [Full Text] [Related]
12. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. BMC Psychiatry; 2014 Nov 29; 14():317. PubMed ID: 25432131 [Abstract] [Full Text] [Related]
13. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B. J Psychiatr Res; 2007 Oct 29; 41(8):625-34. PubMed ID: 16949099 [Abstract] [Full Text] [Related]
19. Reduction of N-acetylaspartate in the medial prefrontal cortex correlated with symptom severity in obsessive-compulsive disorder: meta-analyses of (1)H-MRS studies. Aoki Y, Aoki A, Suwa H. Transl Psychiatry; 2012 Aug 14; 2(8):e153. PubMed ID: 22892718 [Abstract] [Full Text] [Related]
20. Cortical neurochemistry in euthymic patients with bipolar I disorder. Scherk H, Backens M, Schneider-Axmann T, Usher J, Kemmer C, Reith W, Falkai P, Gruber O. World J Biol Psychiatry; 2009 Aug 14; 10(4):285-94. PubMed ID: 19921970 [Abstract] [Full Text] [Related] Page: [Next] [New Search]